{"id":"W2811436997","doi":"10.1016/j.jval.2018.04.1634","title":"Cost-Effectivess Analysis of Brodalumab in Moderate-To-Severe Plaque Psoriasis in Canada","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bausch Health (Canada)","funders":"","keywords":"Medicine; Ixekizumab; Ustekinumab; Adalimumab; Infliximab; Formulary; Secukinumab; Etanercept; Psoriasis Area and Severity Index; Discontinuation; Psoriasis; Internal medicine; Pharmacology; Psoriatic arthritis; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001995183,0.0006194949,0.001544158,0.001984468,0.0009624253,0.002468139,0.001755313,0.0006871721,0.003056345],"category_scores_gemma":[0.007665004,0.0005029622,0.003240518,0.003673781,0.0006615795,0.0004997877,0.0008421571,0.001490973,0.0001201093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.07951365,"about_ca_system_score_gemma":0.07119717,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9868088,"about_ca_topic_score_gemma":0.9885277,"domain_scores_codex":[0.9976258,0.0005304479,0.0001470197,0.0001791554,0.0006906216,0.0008269995],"domain_scores_gemma":[0.9959941,0.001200951,0.0004376522,0.0001001799,0.001450622,0.0008164404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03499119,0.002570386,0.5031027,0.005087331,0.01347973,0.001791281,0.000729522,0.2600354,0.001893383,0.01547426,0.02749233,0.1333525],"study_design_scores_gemma":[0.005917341,0.002454715,0.7419876,0.001453466,0.01132195,0.0006059542,0.002266674,0.2137543,0.00116763,0.002856555,0.01593574,0.0002780734],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9549136,0.0153006,0.001048017,0.003982855,0.0001000137,0.0005115982,0.01686702,0.00005680224,0.00721955],"genre_scores_gemma":[0.9925211,0.002334957,0.0005416842,0.0002077755,0.00002036632,0.00004541623,0.003004122,0.00001235676,0.001312131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07951365,"threshold_uncertainty_score":0.5769145,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3401867671236928,"score_gpt":0.4183694531234424,"score_spread":0.07818268599974959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}